Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integra LifeSciences’ filings rarely stop at simple balance sheets—they dive into FDA approvals, regenerative tissue compliance, and Codman Specialty Surgical revenue splits that can span 300 pages. Finding the section on wound-matrix recall costs or the exact R&D spend per neurosurgical implant is a challenge investors mention often.
Our platform answers that challenge. Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR, then explains the impact in plain English. Want to see "Integra LifeSciences quarterly earnings report 10-Q filing" or compare “Integra LifeSciences annual report 10-K simplified” across years? It’s one click. Looking for "Integra LifeSciences insider trading Form 4 transactions"? Get real-time alerts the instant an executive buys or sells.
Here’s what you can do:
- Track "Integra LifeSciences executive stock transactions Form 4" and spot buying patterns before earnings calls.
- Read "Integra LifeSciences proxy statement executive compensation" without parsing legalese—our AI highlights pay vs. performance.
- Identify product-specific risks in "Integra LifeSciences 8-K material events explained," from manufacturing updates to distribution pauses.
- Use "understanding Integra LifeSciences SEC documents with AI" to compare Codman vs. Tissue Technologies margins over time.
- Dive into "Integra LifeSciences earnings report filing analysis" to gauge demand for regenerative tissue matrices.
Whether you need "Integra LifeSciences Form 4 insider transactions real-time" or a clear summary of the latest "Integra LifeSciences SEC filings explained simply," Stock Titan turns technical disclosures into actionable knowledge—so you can focus on surgical-device fundamentals, not footnotes.
Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), reported two sales of company common stock on 09/01/2025. The filing shows a disposition of 2,139 shares at $15.13, leaving 29,059 shares beneficially owned after that transaction, and a separate disposition of 1,412 shares at $15.13, leaving 27,647 shares beneficially owned after that transaction.
The Form 4 is signed by an attorney-in-fact and includes a Power of Attorney exhibit; it documents insider selling and fulfills disclosure requirements under Section 16.
Integra LifeSciences (IART) Form 4: Director Stuart Essig reported multiple internal transfers of common stock in August 2025. On August 14, 2025 he transferred 200,000 shares to a grantor trust for which his spouse is trustee and received assets of equal fair market value. The same date shows a 200,000-share acquisition entry at $13.62 and a 200,000-share disposition at $13.62 reflecting the trust transfer. Prior to that, on August 8, 2025, 180,080 shares were distributed to Essig from GRAT E as an annuity payment and 500,000 shares were distributed from GRAT F as an annuity payment; GRAT F was then terminated because remaining shares were insufficient to satisfy the annuity obligation. Following the reported transactions, the filings list 1,152,236 shares beneficially owned directly and various indirect holdings through trusts (including 219,920 by GRAT E and 213,115 by a family trust).
FAQ
What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?
What is the market cap of Integra Lifesciences Hldgs Cp (IART)?
